DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria September 9, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Relocates Headquarters to San Diego, California September 4, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials August 27, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering August 14, 2019 • 9:10 AM EDT
DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) August 13, 2019 • 9:00 AM EDT
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) July 31, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme July 24, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019 June 25, 2019 • 5:28 PM EDT